Drug Overview

The therapeutic agent known as CBL0137 is a pioneering “Smart Drug” designed to treat various types of aggressive cancer. Unlike traditional chemotherapy that broadly attacks all fast-growing cells, CBL0137 belongs to a unique class of drugs called “curaxins.” It targets a specific molecular engine inside the cell nucleus that cancer cells rely on for survival and genetic stability.

Currently, CBL0137 is utilized as an advanced targeted therapy in clinical research settings. It is designed to disrupt the cancer cell’s ability to repair itself and manage its DNA, effectively “turning the cell’s own machinery against it.”

Here are the key details about this agent:

Generic Name: CBL0137 (also known as Curaxin CBL0137).
US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
Drug Class: Curaxin / FACT Complex Inhibitor / Epigenetic Modulator.
Route of Administration: Intravenous (IV) infusion or Oral (liquid/capsule) in some experimental protocols.
FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is undergoing active study in Phase 1 and Phase 2 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand CBL0137, it helps to imagine the DNA inside a cell as a long, complicated instruction manual that is tightly wound around spools. These spools are called histones. For a cancer cell to read these instructions and multiply, it needs a specialized “librarian” to move the spools around. This librarian is a protein group called the FACT complex (Facilitates Chromatin Transcription).

Targeting the FACT Complex

Cancer cells have much higher levels of the FACT complex than healthy cells because they are constantly “reading” their DNA to grow and divide. CBL0137 works through a sophisticated process called “c-TACC” (curaxin-mediated small molecule-induced chromatin trapping):

DNA Binding: After CBL0137 enters the cell, it slides into the DNA ladder. This changes the physical shape of the DNA.
Trapping the Librarian: The FACT complex sees this change and tries to fix it. However, the CBL0137 molecule effectively “glues” or traps the FACT complex onto the DNA.
Shutting Down Growth: Once the FACT complex is trapped, it cannot do its job. The cancer cell can no longer “read” the genes it needs for survival.
Activating the “Self-Destruct” Switch: The trapping of the FACT complex triggers a master protein called p53. In healthy cells, p53 acts as a guardian that kills damaged cells. Most cancer cells try to turn p53 off, but CBL0137 forces p53 back “on,” causing the cancer cell to undergo apoptosis (programmed cell death).
Stopping Inflammation: CBL0137 also blocks a pathway called NF-kappaB, which tumors use to promote inflammation and hide from the immune system.

FDA-Approved Clinical Indications

Because CBL0137 is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

Advanced Solid Tumors: Used for cancers such as melanoma, lung cancer, and colorectal cancer that have not responded to standard treatments.
Hematological Malignancies: Investigated for use in leukemias and lymphomas.
Primary Brain Tumors: Studied for its ability to cross the blood-brain barrier to treat aggressive brain cancers.
Pediatric Cancers: Specifically being studied for neuroblastoma and other hard-to-treat childhood tumors.

Non-oncological Uses:

There are currently no non-oncological uses for CBL0137 in clinical development.

Dosage and Administration Protocols

As an investigational drug, the dosage of CBL0137 is strictly managed within clinical trial protocols. It is usually administered as an IV infusion in a hospital or specialized cancer center.

Treatment Detail	Protocol Specification
Standard Dose	Determined by patient weight and trial phase (e.g., 20 mg/m2 to 150 mg/m2)
Route	Intravenous (IV) Infusion
Frequency	Typically once weekly or on a specific “cycle” (e.g., 3 weeks on, 1 week off)
Infusion Time	Usually administered over 60 to 90 minutes
Dose Adjustments	Based on liver function and blood cell counts (handled by the trial physician)

Note: Since the drug is processed primarily by the liver, dose adjustments are often necessary for patients with hepatic insufficiency. Renal adjustments are handled on a case-by-case basis.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) highlight the potential of CBL0137 to treat cancers that have become resistant to traditional chemotherapy.

Overcoming Resistance: Research from major cancer institutes (including trial NCT01901263) shows that CBL0137 can effectively kill cancer cells that have developed resistance to “platinum-based” chemotherapies.
Pediatric Success: In pediatric neuroblastoma studies, CBL0137 demonstrated a significant reduction in tumor volume when combined with other targeted therapies. Numerical data from early phases suggests a “Disease Control Rate” (where tumors shrink or stop growing) in approximately 30 percent of heavily pre-treated patients.
Brain Cancer Penetration: Studies have confirmed that CBL0137 successfully reaches the brain at therapeutic levels, which is a major hurdle for most cancer medications.
Immune Synergy: Recent data suggests that when used with immunotherapy, CBL0137 makes tumors “visible” to the immune system again, increasing the effectiveness of T-cell-based treatments.

Safety Profile and Side Effects

Because CBL0137 is a targeted therapy, it aims to avoid many of the harsh side effects of standard chemotherapy. However, because it affects how DNA is handled, it does have a specific safety profile.

Common Side Effects (greater than 10 percent):

Fatigue: Mild to moderate tiredness shortly after infusion.
Nausea: Usually manageable with standard anti-nausea medications.
Anemia: A decrease in red blood cells, which can cause weakness.
Liver Enzyme Changes: Temporary increases in ALT or AST levels in blood tests.

Serious Adverse Events:

Neutropenia: A drop in white blood cell counts, which can increase the risk of infection.
Allergic Reactions: Rare reactions during infusion, such as itching or shortness of breath.
Electrolyte Imbalance: Changes in blood salt levels that require monitoring.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Management Strategies:

For Liver Health: Doctors perform weekly blood tests to ensure liver enzymes stay within a safe range.
For Infection Prevention: Patients are monitored for fever. If white blood cell counts drop too low, a “growth factor” injection may be used.
Hydration: Patients are encouraged to drink plenty of water to help the kidneys process the drug safely.

Research Areas

CBL0137 is currently a major focus in Immunotherapy and Epigenetic Research. Because it changes how DNA is “wrapped” and “read,” scientists are looking at how it can be used to “re-program” a patient’s own immune system to fight cancer better.

In the field of regenerative medicine, research is exploring if CBL0137 can be used in tiny doses to selectively kill “senescent” cells—aged cells that can promote cancer and aging—while sparing healthy stem cells. This is part of a broader study into “organ-protective” therapies during cancer treatment.

Patient Management and Practical Recommendations

To ensure the best results and the highest level of safety, patients enrolled in CBL0137 trials should follow specific guidelines.

Pre-treatment Tests to be Performed:

Baseline Blood Panel: Comprehensive check of white blood cells, red blood cells, and platelets.
Liver Function Test (LFT): To ensure the liver is healthy enough to process the medication.
EKG: A heart rhythm check, as some targeted therapies can affect heart electrical patterns.

Precautions During Treatment:

Avoid certain medications: Some herbal supplements and over-the-counter drugs can affect liver enzymes. Always consult the study team before taking new medications.
Contraception: This drug affects DNA and can harm an unborn baby. Highly effective birth control is required for both men and women during and for several months after treatment.

“Do’s and Don’ts” List:

DO keep all scheduled follow-up appointments for blood work.
DO report any new or worsening fatigue or yellowing of the skin (jaundice) immediately.
DON’T take high doses of Vitamin C or other antioxidants unless approved, as they may interfere with how the drug creates the p53 “switch.”
DON’T miss your scheduled infusions, as the timing is critical for the drug to trap the FACT complex effectively.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. CBL0137 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.